(S) -Veliflapon

(S) -Veliflapon ((S) -BAY X 1005) is an orally active inhibitor of leukotriene biosynthesis and 5-lipoxygenase activating protein (FLAP) . (S) -Veliflapon inhibits the formation of leukotriene B4 (LTB4) in rat, mouse and human leukocytes with IC50 values of 0.026 µM, 0.039 µM and 0.22 µM respectively. (S) -Veliflapon showes enantioselectivity in human whole blood[1][2][3].

Product Specifications

CAS Number

[128253-32-7]

Product Name Alternative

(S) -BAY X 1005; (S) -DG-031

UNSPSC

12352005

Target

FLAP; Leukotriene Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/s-veliflapon.html

Purity

99.44

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)[C@@H](C1CCCC1)C(C=C2)=CC=C2OCC3=NC4=CC=CC=C4C=C3

Molecular Formula

C23H23NO3

Molecular Weight

361.43

References & Citations

[1]Fruchtmann R, et al. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions. 1993 Mar;38 (3-4) :188-95. |[2]Hermann, David J., et al. Dosing schedules of leukotriene synthesis inhibitors for human therapy. World Intellectual Property Organization. WO2009002746.|[3]Helgadottir, et al. Polymorphisms in the susceptibility genes for myocardial infarction, stroke, and peripheral artery occlusive disease and their use in risk assessment and prophylaxis therapy. United States. US20070280917.